Swobodnik W, Janowitz P, Kratzer W, Wenk H, Neuhaus H, Malfertheiner P, Hagert N, Fischer S, Ditschuneit H, Schusdziarra V
II. Medizinische Klinik der Technischen Universität München.
Z Gastroenterol. 1990 Nov;28(11):621-5.
The effect of ursodeoxycholic acid on recurrence prevention of choledochal calculi after endoscopic sphincterotomy (EPT) was evaluated in 46 patients, whose bile duct stones had been removed endoscopically. 22 patients received 500 mg of ursodeoxycholic acid once a day, 24 patients received placebo. 1 recurrent stone could be detected in the ursodeoxycholic acid treated group 19 months after EPT, whereas 4 recurrent stones occurred in the placebo group about 16 months after EPT. Cholesterol saturation index decreased significantly by the ursodeoxycholic acid treatment 12 and 24 months after EPT (0.93 +/- 0.17 vs. 0.69 +/- 0.12 vs. 0.72 +/- 0.07). The nucleation time increased statistically significant from 9.0 days to 20.4 (12 months) and 17.7 (24 months) days, respectively. Obviously, pharmacological effects of ursodeoxycholic acid exist which modify important processes in the gallstone's pathogenesis.
对46例经内镜取出胆管结石的患者评估了熊去氧胆酸对内镜括约肌切开术(EPT)后胆总管结石复发的预防作用。22例患者每天服用一次500毫克熊去氧胆酸,24例患者服用安慰剂。在EPT后19个月,熊去氧胆酸治疗组检测到1例复发结石,而安慰剂组在EPT后约16个月出现4例复发结石。EPT后12个月和24个月,熊去氧胆酸治疗使胆固醇饱和指数显著降低(分别为0.93±0.17、0.69±0.12和0.72±0.07)。成核时间分别从9.0天增加到20.4天(12个月)和17.7天(24个月),具有统计学意义。显然,熊去氧胆酸存在药理作用,可改变胆结石发病机制中的重要过程。